Sulfonylurea

Use over 10-year period also leads to cardiac events in type 2 patients using metformin monotherapy… Cardiovascular disease is a common comorbid complication in type 2 diabetes patients. 50-80% of type 2 diabetes patient deaths are a result of a cardiovascular disease. Sulfonylureas are one of the most widely prescribed …

Study finds drug combination increases costs and morbidity rates…. In a retrospective cohort study, researchers assessed Texas Medicare claims from 2006 to 2009 for patients 66 years or older who were prescribed glipizide or glyburide and who also filled a prescription for 1 of the 16 antimicrobials most commonly prescribed. …

This week, we’re taking a break from our regularly featured section on avoiding medication mistakes to bring you this exclusive interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin. Steve Freed, Publisher, Diabetes …

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …

The addition of a DPP-4 inhibitor decreased HbA1C while not requiring an increase in insulin, and subjects remained weight neutral without experiencing an increase in hypoglycemic events… Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and …

Metformin, sulfonylureas, thiazolidinedione, and DPP-4 inhibitors were compared to evaluate the effects on the time to subsequent treatment… There are many classes of oral drugs used for diabetes therapy, but there is a lack of evidence as to which drug is best for use as initial therapy. Most patients diagnosed …

Exenatide twice daily shows similar glycemic control with weight loss and less hypoglycemia as compared to mealtime insulin… Some patients with advanced type 2 diabetes still do not achieve glycemic control with insulin glargine and metformin. Mealtime insulin lispro is often added on to the regimen but it is associated …

Use of blue LED light activates sulfonylureas… The use of sulfonylureas has long been an option for controlling type 2 diabetes. Their use is often associated with hypoglycemia and weight gain. A new technology seeks to minimize these side effects. Researchers are looking at a prototype sulfonylurea, JB253, which stimulates …

Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …

Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …